Researchers at Salk Institute for Biological Studies found the molecular target of the experimental drug J147. Their findings showed that J147, which is currently nearing clinical trials for Alzheimer’s disease, reverses memory deficits and slows down the progression of Alzheimer’s disease in animal models. The team also discovered that the drug “binds to a protein found in mitochondria,” which makes aging cells appear more youthful. The researchers believe J147 has the potential to move forward as a treatment for Alzheimer’s disease, as well as age-associated diseases. To learn more, go here.
The Alliance for Aging Research is a proud recipient of Candid’s Platinum Seal of Transparency.
